<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35067827</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Very low peroneal nerve compound muscle action potential amplitude predicts poor outcome in patients with Guillain-Barré syndrome: a prospective cohort.</ArticleTitle>
        <Pagination>
          <StartPage>3923</StartPage>
          <EndPage>3928</EndPage>
          <MedlinePgn>3923-3928</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-021-05834-7</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Twenty percent of patients with Guillain-Barré syndrome (GBS) have poor outcomes despite proper management. The aim of the study was to characterize electrophysiological factors related to poor outcome in patients with GBS.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted an observational study from a prospective cohort of 91 patients with GBS in a tertiary healthcare center in Mexico, from 2017 to 2019. Demographics and nerve conduction studies were performed on admission, and a 3-month follow-up for GBS disability score was ensued, allocating patients in good (GBS disability score ≤ 2) and poor outcome (GBS disability score ≥ 3) groups. A logistic regression analysis for independent walk at 3 months was performed. Kaplan-Meier estimator curves for independent walk in very low (&lt; 20% LLN) and low-normal ( ≥20% LLN) peroneal nerve CMAPs are presented.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">From the 91 GBS patients included, 37 (40.6%) did not regain independent walk at 3 months. Axonal variants were more common in the poor outcome group (31.4% vs 59.4%, p = 0.01) as well as AIDP variants with motor conduction block (6.6% vs 42.4%, p = 0.018). Univariable analysis was statistically significant for very low median, ulnar, tibial, and peroneal CMAP amplitudes in poor outcome patients; however, multivariable analysis was only significant for very low peroneal nerve CMAP amplitude (OR 3.6 [1.1-11.5, p = 0.024]). Conversely, a greater proportion of GBS patients with low-normal CMAPs recovered independent walk at 90 days (75% vs 30%, p &lt; 0.001).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Severe axonal injury of the peroneal nerve, axonal, and AIDP with motor conduction block variants predicts worse functional outcome regarding independent walk at 3 months.</AbstractText>
          <CopyrightInformation>© 2021. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>López-Hernández</LastName>
            <ForeName>Juan Carlos</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galnares-Olalde</LastName>
            <ForeName>Javier Andrés</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jorge de Saráchaga</LastName>
            <ForeName>Adib</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Briseño-Godínez</LastName>
            <ForeName>María Eugenia</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pérez-Valdez</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>May-Mas</LastName>
            <ForeName>Raúl Nathanael</ForeName>
            <Initials>RN</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arista-Ramírez</LastName>
            <ForeName>José Luis</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bazán-Rodríguez</LastName>
            <ForeName>Lisette</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>León-Manriquez</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burgos-Centeno</LastName>
            <ForeName>Jorge</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Neurophysiology Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vargas-Cañas</LastName>
            <ForeName>Edwin Steven</ForeName>
            <Initials>ES</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Diseases Department, Instituto Nacional de Neurología Y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico. clinicaneuromuscular.innn@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010543" MajorTopicYN="Y">Peroneal Nerve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Axonal</Keyword>
        <Keyword MajorTopicYN="N">Demyelinating</Keyword>
        <Keyword MajorTopicYN="N">Guillain-Barré syndrome</Keyword>
        <Keyword MajorTopicYN="N">Nerve conduction studies</Keyword>
        <Keyword MajorTopicYN="N">Peroneal nerve</Keyword>
        <Keyword MajorTopicYN="N">Poor outcome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35067827</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-021-05834-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-021-05834-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sejvar J, Baughman A, Wise M et al (2011) Population incidence of Guillain- Barré syndrome: a systematic review and meta- analysis. Neuroepidemiology 36:123–133</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000324710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Berg B, Walgaard C, Drenthen J et al (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment, and prognosis. Nat Rev Neurol 10(8):469–482</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2014.121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chio A et al (2003) Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000055091.96905.D0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Koningsveld R et al (2007) A clinical prognostic scoring system for Guillain– Barré syndrome. Lancet Neurol 6:589–594</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(07)70130-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walgaard C, Lingsma HF, Ruts L et al (2011) Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76(11):968–975</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182104407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Cornblath DR (2005) Guillain Barré syndrome. Lancet 366(9497):1653–1666</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)67665-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwabara S, Yuki N (2013) Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 12(12):1180–1188</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(13)70215-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berciano J. Axonal degeneration in Guillain-Barré syndrome: a reappraisal. J Neurol. 2020. https://doi.org/10.1007/s00415-020-10034-y . Online ahead of print.</Citation>
        </Reference>
        <Reference>
          <Citation>Dimachkie MM, Barohn RJ (2013) Guillain-Barré syndrome and variants. Neurol Clin 31(2):491–510</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ncl.2013.01.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan YC, Punzalan-Sotelo AM, Kannan TA et al (2017) Electrodiagnosis of reversible conduction failure in Guillain-Barré syndrome. Muscle Nerve 56(5):919–924</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornblath DR, Mellits ED, Griffin JW et al (1988) Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 23(4):354–359</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410230407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uncini A, Kuwabara S (2012) Electrodiagnostic criteria for Guillain-Barré syndrome: a critical revision and the need for an update. Clin Neurophysiol 123(8):1487–1495</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2012.01.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadden RDM, Cornblath DR, Hughes RAC et al (1998) Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 44:780–788</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410440512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajabally YA, Durand M-C, Mitchell J et al (2014) Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry 86(1):115–119</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2014-307815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27(Suppl):S21–S24</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410270707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler K, Morris J, Scott K, et al. Neuroanatomy for nerve conduction studies. AANEM Course. 2010. Pp: 1–36</Citation>
        </Reference>
        <Reference>
          <Citation>Mallik A, Weir A. Nerve conduction studies: essentials and pitfalls in practice. J Neurol Neurosurg Psychiatry 2005;76(Suppl II):ii23–ii31.</Citation>
        </Reference>
        <Reference>
          <Citation>Collins GS, Reitsma JB, Altman DG et al (2015) Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 162(1):55–63</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M14-0697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosokawa T, Nakajima H, Unoda K et al (2014) An electrophysiological classification associated with Guillain-Barré syndrome outcomes. J Neurol 261(10):1986–1993. https://doi.org/10.1007/s00415-014-7452-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-014-7452-2</ArticleId>
            <ArticleId IdType="pubmed">25082629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu J, Liu M, Sun Q et al (2018) Motor nerve conduction block predicting outcome of Guillain-Barre syndrome. Front Neurol 9:399. https://doi.org/10.3389/fneur.2018.00399</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00399</ArticleId>
            <ArticleId IdType="pubmed">29910770</ArticleId>
            <ArticleId IdType="pmc">5992574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma R, Chaudhari TS, Raut TP, Garg RK (2013) Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS). J Neurol Sci 335(1–2):105–111</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2013.09.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uncini A, Manzoli C, Notturno F, Capasso M (2010) Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 81(10):1157–1163. https://doi.org/10.1136/jnnp.2010.208538</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2010.208538</ArticleId>
            <ArticleId IdType="pubmed">20870864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Susuki K, Yuki N, Schafer DP et al (2012) Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233(1):534–542. https://doi.org/10.1016/j.expneurol.2011.11.039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2011.11.039</ArticleId>
            <ArticleId IdType="pubmed">22178332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokubun N, Nishibayashi M, Uncini A et al (2010) Conduction block in acute motor axonal neuropathy. Brain 133(10):2897–2908. https://doi.org/10.1093/brain/awq260</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awq260</ArticleId>
            <ArticleId IdType="pubmed">20855419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barré syndrome. Lancet 388(10045):717–727</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)00339-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwabara S, Uncini A (2013) Multiple mechanisms for distal axonal loss in Guillain- Barré syndrome. Clin Neurophysiol 124(4):821–822. https://doi.org/10.1016/j.clinph.2012.08.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2012.08.008</ArticleId>
            <ArticleId IdType="pubmed">22981651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walgaarr C, Lingsma HFM, Ruts L, van Doorn PA et al (2011) Early recognition of poor prognosis in Guillan-Barre syndrome. Neurology. 76(11):968–75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182104407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajabally YA, Hiew FL (2017) Optimizing electrodiagnosis for Guillain-Barré syndrome: clues from clinical practice. Muscle Nerve 55(5):748–751. https://doi.org/10.1002/mus.25433</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25433</ArticleId>
            <ArticleId IdType="pubmed">27750406</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
